The new Coronavirus disease or COVID-19 is a contagious viral/immune-logical systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2, which is rapidly spreading from person-...The new Coronavirus disease or COVID-19 is a contagious viral/immune-logical systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2, which is rapidly spreading from person-to-person all around the world as a pandemic. The new outbreak of COVID-19 first appeared in Wuhan, China in December 2019. This virus is transmitted from human to human in various ways including air, aerosol, touching, and fecal-oral ways. The SARS-CoV-2 survives for several days in the environment. The SARS-CoV-2 virus multiplies within the cells of mouth-throat or nose-throat, and despite the production of antibodies by the human immune system, if the virus continues to multiply and progress, it will enter the bloodstream and reach its target organ, the lungs. It takes an incubation period of one to fourteen days for the initial symptoms/signs of disease to appear as fever, dry cough, and fatigue. Finally, shortness of breath due to pneumonia/pneumonitis with or without Acute Respiratory Distress Syndrome (ARDS) causes the patient to be hospitalized and transferred to ICU. Older people with underlying disorders account for the majority of deaths from COVID-19, while children under the age of 15 - 20 are the main carriers of the SARS-CoV-2. About 40% of patients with COVID-19 are asymptomatic and, 40% mild, 15%;severe, and 5% are critical COVID-19. COVID-19 Molecular Diagnostic Tests and COVID-19 Antibody Tests are two types of diagnostic kit tests for identification of the SARS-CoV-2 and the High Resolution Computerised Tomography (HRCT) scanning of lungs is the best imaging method for detecting pneumonia/pneumonitis and assessing its severity. This paper is intended to present a health system called COVID-19 Referral System for screening and developing very sensitive diagnostic criteria as Persian Gulf Criteria for diagnosis of COVID-19. By using these two methods and performing the SARS-CoV-2 kit tests more and more widely, and performing accurate isolation of patients and virus carriers and complete quarantine of red zones, it is possible to successfully control the SARS-CoV-2 epidemics.展开更多
<span style="font-family:Verdana;">Purpose: </span><span style="font-family:Verdana;">To discuss the effect of “1 + 3 + 3” emergency management mode to deal with COVID-19 pandem...<span style="font-family:Verdana;">Purpose: </span><span style="font-family:Verdana;">To discuss the effect of “1 + 3 + 3” emergency management mode to deal with COVID-19 pandemic in fever outpatient service of general hospitals. Method: This paper analyzes and summarizes the problems encountered by fever outpatient service in dealing with the COVID-19 pandemic from three aspects of “One Team”, “Three-Key” Control and “Three Mosts”. Results: The application of “1 + 3 + 3” emergency management mode can effectively boost the orderliness and efficiency of fever outpatient service in dealing with COVID-19 pandemic. Conclusion: The “1 + 3 + 3” emergency management mode provides a new management mode and idea for dealing with COVID-19 pandemic,</span><span style="font-family:""> </span><span style="font-family:Verdana;">so the fever outpatient service of general hospitals can better improve the national overall anti-pandemic situation.展开更多
目的:基于2019-nCoV冠状病毒3CL水解酶(3CL protease,Mpro)的三维结构,采用分子对接技术和网络药理学方法探寻祛肺毒一号方治疗新型冠状病毒肺炎(corona virus disease 2019,COVID-19)的物质基础和作用机制。方法:采用中药系统药理学数...目的:基于2019-nCoV冠状病毒3CL水解酶(3CL protease,Mpro)的三维结构,采用分子对接技术和网络药理学方法探寻祛肺毒一号方治疗新型冠状病毒肺炎(corona virus disease 2019,COVID-19)的物质基础和作用机制。方法:采用中药系统药理学数据库与分析平台(traditional chinese medicine systems pharmacology database and analysis platform,TCMSP)及文献检索搜集祛肺毒一号方组方中药的化学成分,并以类药性(drug likeness,DL)≥0.18及口服生物利用度(oral bioavailability,OB)≥30%为标准进行筛选,采用分子对接技术将筛选出的化合物与2019-nCoV 3CL Mpro对接,以结合能小于-9 kcal·mol^(-1)为标准,筛选祛肺毒一号方的活性成分。运用SwissTargetPrediction数据库预测活性成分的作用靶点,并在人类基因数据库(the human gene database,GeneCards)、美国国立生物技术信息中心(national center for biotechnology information,NCBI)数据库及CTD数据库检索COVID-19相关靶点,采用venny 2.1软件得到活性成分作用靶点与COVID-19相关靶点的交集靶点。将交集靶点导入STRING 11.0数据库,最终获得蛋白质相互作用网络图。采用DAVID数据库对交集靶点进行基因本体(gene ontology,GO)功能富集分析和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)信号通路富集分析。运用Cytoscape3.7.2软件构建“中药活性成分-疾病-通路-靶点”网络图。结果:通过检索TCMSP数据库与文献查找筛选出220个祛肺毒一号方的化学成分,以结合能≤-9 kcal·mol^(-1)为标准筛选得到33个活性成分,且结合能最低的3个化合物可共同作用于靶蛋白2019-nCoV 3CL Mpro。33个祛肺毒一号方活性成分的728个靶点与4165个COVID-19疾病相关靶点进行映射,最终得到祛肺毒一号方治疗COVID-19的有效靶点347个,核心靶点基因筛选得到CCR1、HCRTR2、MAPK3、BCL2L1等11个核心基因。KEGG通路富集显示靶点显著富集于磷酯酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(protein kinase B,Akt)信号通路、缺氧诱导因子-1(hypoxia inducible factor-1,HIF-1)信号通路、T细胞受体信号通路等179条通路。GO生物功能富集分析发现3210条GO生物功能,包括氧化应激反应、细胞对药物的反应等2871条生物过程,丝氨酸蛋白酶激酶活性、酪氨酸激酶活性等230条分子功能和膜筏、膜区等109条细胞组分。结论:祛肺毒一号方可能通过多成分调控多靶点、多通路防治新型冠状病毒肺炎。展开更多
背景白细胞介素6(interleukin-6,IL-6)在新型冠状病毒肺炎患者细胞因子风暴的发生发展中扮演着重要角色,是重症化的预测指标之一。有研究表明纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)在急性感染中能够被IL-6诱导产生,在肝细...背景白细胞介素6(interleukin-6,IL-6)在新型冠状病毒肺炎患者细胞因子风暴的发生发展中扮演着重要角色,是重症化的预测指标之一。有研究表明纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)在急性感染中能够被IL-6诱导产生,在肝细胞稳态维持方面具有重要作用。目的探讨FGL1在新型冠状病毒肺炎患者血浆中的表达及其与疾病严重程度的关系。方法选取2020年1-3月解放军总医院第五医学中心收治的37例新型冠状病毒肺炎患者和14例健康对照者,其中新型冠状病毒肺炎患者根据疾病严重程度分为轻型和中/重型,采用酶联免疫吸附法检测血浆中FGL1和IL-6等相关细胞因子的表达水平,应用受试者工作特征(receiver operator characteristic,ROC)曲线分析FGL1对新型冠状病毒肺炎的评估价值。结果与健康对照者相比,新型冠状病毒肺炎患者血浆中FGL1表达明显上调[(240.26±83.78)ng/mL vs(74.87±29.28)ng/mL,P<0.001];中/重型患者血浆FGL1水平较轻型患者显著升高[(271.33±85.27)ng/mL vs(189.22±51.19)ng/mL,P=0.004]。ROC曲线分析显示,血浆FGL1评估中/重型新型冠状病毒肺炎的曲线下面积(95%CI)为0.780(0.631~0.928),其敏感度和特异性为78.57%和73.91%。Pearson相关性分析显示,新型冠状病毒肺炎患者血浆FGL1水平与IL-6、IFN-γ含量呈正相关(r=0.588,P<0.001;r=0.378,P=0.017)。结论FGL1在新型冠状病毒肺炎患者血浆中明显上调,且与疾病严重程度呈正相关,可作为评估新型冠状病毒肺炎病情的参考指标。展开更多
文摘The new Coronavirus disease or COVID-19 is a contagious viral/immune-logical systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2, which is rapidly spreading from person-to-person all around the world as a pandemic. The new outbreak of COVID-19 first appeared in Wuhan, China in December 2019. This virus is transmitted from human to human in various ways including air, aerosol, touching, and fecal-oral ways. The SARS-CoV-2 survives for several days in the environment. The SARS-CoV-2 virus multiplies within the cells of mouth-throat or nose-throat, and despite the production of antibodies by the human immune system, if the virus continues to multiply and progress, it will enter the bloodstream and reach its target organ, the lungs. It takes an incubation period of one to fourteen days for the initial symptoms/signs of disease to appear as fever, dry cough, and fatigue. Finally, shortness of breath due to pneumonia/pneumonitis with or without Acute Respiratory Distress Syndrome (ARDS) causes the patient to be hospitalized and transferred to ICU. Older people with underlying disorders account for the majority of deaths from COVID-19, while children under the age of 15 - 20 are the main carriers of the SARS-CoV-2. About 40% of patients with COVID-19 are asymptomatic and, 40% mild, 15%;severe, and 5% are critical COVID-19. COVID-19 Molecular Diagnostic Tests and COVID-19 Antibody Tests are two types of diagnostic kit tests for identification of the SARS-CoV-2 and the High Resolution Computerised Tomography (HRCT) scanning of lungs is the best imaging method for detecting pneumonia/pneumonitis and assessing its severity. This paper is intended to present a health system called COVID-19 Referral System for screening and developing very sensitive diagnostic criteria as Persian Gulf Criteria for diagnosis of COVID-19. By using these two methods and performing the SARS-CoV-2 kit tests more and more widely, and performing accurate isolation of patients and virus carriers and complete quarantine of red zones, it is possible to successfully control the SARS-CoV-2 epidemics.
文摘<span style="font-family:Verdana;">Purpose: </span><span style="font-family:Verdana;">To discuss the effect of “1 + 3 + 3” emergency management mode to deal with COVID-19 pandemic in fever outpatient service of general hospitals. Method: This paper analyzes and summarizes the problems encountered by fever outpatient service in dealing with the COVID-19 pandemic from three aspects of “One Team”, “Three-Key” Control and “Three Mosts”. Results: The application of “1 + 3 + 3” emergency management mode can effectively boost the orderliness and efficiency of fever outpatient service in dealing with COVID-19 pandemic. Conclusion: The “1 + 3 + 3” emergency management mode provides a new management mode and idea for dealing with COVID-19 pandemic,</span><span style="font-family:""> </span><span style="font-family:Verdana;">so the fever outpatient service of general hospitals can better improve the national overall anti-pandemic situation.
文摘目的:基于2019-nCoV冠状病毒3CL水解酶(3CL protease,Mpro)的三维结构,采用分子对接技术和网络药理学方法探寻祛肺毒一号方治疗新型冠状病毒肺炎(corona virus disease 2019,COVID-19)的物质基础和作用机制。方法:采用中药系统药理学数据库与分析平台(traditional chinese medicine systems pharmacology database and analysis platform,TCMSP)及文献检索搜集祛肺毒一号方组方中药的化学成分,并以类药性(drug likeness,DL)≥0.18及口服生物利用度(oral bioavailability,OB)≥30%为标准进行筛选,采用分子对接技术将筛选出的化合物与2019-nCoV 3CL Mpro对接,以结合能小于-9 kcal·mol^(-1)为标准,筛选祛肺毒一号方的活性成分。运用SwissTargetPrediction数据库预测活性成分的作用靶点,并在人类基因数据库(the human gene database,GeneCards)、美国国立生物技术信息中心(national center for biotechnology information,NCBI)数据库及CTD数据库检索COVID-19相关靶点,采用venny 2.1软件得到活性成分作用靶点与COVID-19相关靶点的交集靶点。将交集靶点导入STRING 11.0数据库,最终获得蛋白质相互作用网络图。采用DAVID数据库对交集靶点进行基因本体(gene ontology,GO)功能富集分析和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)信号通路富集分析。运用Cytoscape3.7.2软件构建“中药活性成分-疾病-通路-靶点”网络图。结果:通过检索TCMSP数据库与文献查找筛选出220个祛肺毒一号方的化学成分,以结合能≤-9 kcal·mol^(-1)为标准筛选得到33个活性成分,且结合能最低的3个化合物可共同作用于靶蛋白2019-nCoV 3CL Mpro。33个祛肺毒一号方活性成分的728个靶点与4165个COVID-19疾病相关靶点进行映射,最终得到祛肺毒一号方治疗COVID-19的有效靶点347个,核心靶点基因筛选得到CCR1、HCRTR2、MAPK3、BCL2L1等11个核心基因。KEGG通路富集显示靶点显著富集于磷酯酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(protein kinase B,Akt)信号通路、缺氧诱导因子-1(hypoxia inducible factor-1,HIF-1)信号通路、T细胞受体信号通路等179条通路。GO生物功能富集分析发现3210条GO生物功能,包括氧化应激反应、细胞对药物的反应等2871条生物过程,丝氨酸蛋白酶激酶活性、酪氨酸激酶活性等230条分子功能和膜筏、膜区等109条细胞组分。结论:祛肺毒一号方可能通过多成分调控多靶点、多通路防治新型冠状病毒肺炎。
